(Q38223511)

31 August 2017

title

P95 HER2 fragments and breast cancer outcome (English)

1 reference

31 August 2017

1 reference

Deniz Tural

1

1 reference

31 August 2017

Emre Akar

series ordinal

2

1 reference

31 August 2017

Hasan Mutlu

series ordinal

3

1 reference

31 August 2017

Saadettin Kilickap

series ordinal

4

1 reference

31 August 2017

publication date

26 June 2014

1 reference

Expert Review of Anticancer Therapy

31 August 2017

published in

1 reference

31 August 2017

volume

14

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

1089-1096

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

HER2 therapy: molecular mechanisms of trastuzumab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Role of ADAMs in cancer formation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Ligand-induced ErbB receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.929946

10.1586/14737140.2014.929946

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference